World Courier Achieves Coveted GxP-Compliant Status Worldwide With Focus On GDP, Quality Management
For over 40 years, World Courier has set the standard for worldwide time- and temperature-sensitive transportation services to the pharmaceutical industry. By World Courier
WHITE PAPERS & CASE STUDIES
Securing Provision K Status For A Client’s API Helps To Expedite Shipping And Reduce US Importation Costs
Active pharmaceutical ingredients (APIs) also known as bulk active pharmaceutical ingredients, are defined by the US Food and Drugs Administration (FDA) as ‘any component that provides pharmacological activity or other effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or any function of the body of man or animals.’ Generally, APIs are therapeutic components of drug formulations or finished pharmaceutical products that also contain fillers, binders’ excipients and other inactive ingredients. APIs are routinely evaluated or used by pharmaceutical companies for preclinical testing during new drug development, human clinical trials testing and commercial manufacturing of approved pharmaceutical products.
IMP Shipments: Too Big, Too Costly, Too Bad
A client in the UK was initiating a new clinical trial, and shipping forty-two pallets of the IMP to Marken’s pharmaceutical service depot in the testing region created several challenges.
Despite An Airport Strike, Marken Preserves The Data Chain
Marken collected a shipment from southern Sweden that was bound for next-day delivery in northern Belgium. However, all airline flights into Belgium were cancelled as a result of a strike action by airport workers.
From Premium Logistics To A True Partner In Global Life Science Supply Chain Management
Part one of Marken CEO Wes Wheeler’s ten part blog series about the changing face of Life Science Logistics in today’s fast-paced pharmaceutical industry. By Wesley Wheeler, CEO, Marken
Efficiencies Of Natural Convection In Passive Pallet Shippers
Bulk transportation of temperature sensitive pharmaceuticals and biologics has become a common practice due to complex global supply chains. By Iftekhar Ahmed, Ben VanderPlas, and Stu Krupnick
A Model For Pharmaceutical Supply Chain Quality Agreements
Over a decade ago, the way business was conducted between pharmaceutical manufacturing companies and their supply chain providers was typically expressed through verbal expectations at the due diligence meeting, at the audit, or at the first project meeting, and they were pretty much done by written bullet points. By Rafik H. Bishara, Steve Jacobs, and Dan Bell
PRODUCTS & SERVICESMore Products & Services
LIFE SCIENCE WEBINARS
Delivering Biologics With A Difference
In this webinar you will learn about delivering intravenous-dosed biologics in an aseptically-filled intravenous bag and increase your understanding of the business drivers and potential value added with this strategy.
MAb Manufacturing: Where Are We Headed, Cost Or Capabilities?
Following the discussion on monoclonal antibody (MAb) processing, partly conflicting observations can be made: some push costs in the foreground of process technology discussion, while others emphasize robustness and peace of mind (low risk).
Digital Signatures: Enabling Compliant Collaboration and Streamlined Corporate Governance
In this webinar, we’ll focus on the middle office where life sciences organizations can achieve tangible operational improvements and cost savings.